NCT01491672

Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma

An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 134 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate everolimus as second-line therapy in patients with metastatic renal cell carcinoma. Each patient will be enrolled and stratified in one of three cohorts based upon their first-line therapy: 1) prior cytokines, 2) prior sunitinib, or 3) prior anti-VEGF therapy other than sunitinib.

Conditions

• Metastatic Renal Cell Carcinoma

Interventions

Type	Name	Description
DRUG	RAD001	Study drug was supplied as 5 mg tablets in blister packs.

Timeline

• Start date: 2011-11-01
• Primary completion: 2015-05-01
• Completion: 2015-05-01
• First posted: 2011-12-14
• Last updated: 2016-06-06
• Results posted: 2016-06-02

Locations

17 sites across 6 countries: United States, Argentina, Brazil, Bulgaria, China, Russia